Kidney Diseases肾脏疾病
Kidney Diseases(英文缩写 KIDNEY DIS-BASEL),ISSN 2296-9381,eISSN 2296-9357,中文译名:肾脏疾病 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.000 | Q2 |
| 2022 | 3.700 | Q1 |
| 2023 | 3.200 | Q1 |
| 2024 | 3.100 | Q1 |
| 2025 | 3.700 | Q1 |
Kidney Diseases 最新收录文献
-
1. Urinary Glucose Concentration as a Predictor of Proteinuria Reduction in Chronic Kidney Disease Patients Treated with Sodium-Glucose Cotransporter 2 Inhibitors.
1. 尿葡萄糖浓度作为用钠葡萄糖协同转运蛋白2抑制剂治疗的慢性肾病患者蛋白尿减少的预测因素PMID:日期:2026-07-14Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are crucial in managing proteinuria in chronic kidney disease (CKD), yet individual responses vary. Whether urinary glucose excretion, a direct pharmacodynamic marker of SGLT2is, could predict proteinuria reduction efficacy remains unclear and has not been specifically investigated. We enrolled 277 CKD patients treated with empagliflozin (10 mg/day) between July 2024 and September 2025 at a single center, stratifying them into low (<46.4 mmol/L, = 69) and high (≥46.4 mmol/L, = 208) urinary glucose groups by 24-h urinary glucose levels after 3 months of treatment. We evaluated changes in proteinuria levels following 3 and 6 months of medication across the different urinary glucose groups. Changes in laboratory values over time were analyzed using paired Wilcoxon signed-rank tests. Proteinuria was significantly reduced at both 3 (-0.42 g/24 h [95% confidence interval [CI]: -0.55 to -0.32]) and 6 months (-0.46 g/24 h [95% CI: -0.61 to -0.33]) after treatment initiation. After adjusting for covariates, urinary glucose excretion predicted proteinuria reduction from 3 to 6 months (β = 2.47, 95% CI: 0.49-4.45, = 0.015), with higher urinary glucose correlating with greater proteinuria decline. The high urinary glucose group had significant proteinuria reduction from baseline at 3 and 6 months ( < 0.001), unlike the low group. Following propensity score adjustment for age, sex, body mass index, baseline estimated glomerular filtration rate (eGFR), and renin-angiotensin-aldosterone system inhibitors use, the high urinary glucose group had a significantly higher relative risk of ≥30% proteinuria reduction (risk ratio = 2.82, 95% CI: 1.20-6.65, = 0.017), particularly in patients with baseline proteinuria ≥1 g/24 h. Urinary glucose concentration was weakly positively correlated with 6-month eGFR change ( = 0.17, = 0.011). Urinary glucose concentration can serve as a predictor of SGLT2i-mediated proteinuria reduction, providing a practical clinical reference for personalized CKD management.
-
2. Enoxolone Alleviates Renal Fibrosis in Diabetic Kidney Disease by Inhibiting the Smad3-Smad4 Complex.
2. 甘草次酸通过抑制Smad3-Smad4复合物减轻糖尿病肾病中的肾纤维化PMID:日期:2026-07-11This study aimed to explore the ameliorative effects of enoxolone on renal fibrosis in diabetic kidney disease (DKD) and elucidate its underlying molecular mechanisms, thereby proposing a novel candidate drug and providing a theoretical foundation for clinical anti-fibrotic therapy in DKD. We analyzed the single-cell transcriptome dataset GSE209781 and integrated it with the connectivity map database to identify potential therapeutic compounds for DKD. Molecular docking and surface plasmon resonance techniques were employed to verify the binding interaction between enoxolone and Smad3. In vitro experiments involved human renal tubular epithelial HK2 cells and primary mouse tubular epithelial cells derived from Smad3-knockout (Smad3-KO) mice, which were stimulated with high glucose and advanced glycation end-products (HG+AGEs). Co-immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), quantitative real-time polymerase chain reaction (qPCR), and Western blot analyses were conducted to assess the effects of enoxolone on the Smad3-Smad4 interaction, binding of Smad3 to the COL1A1 promoter, and expression of fibrotic genes. An in vivo streptozotocin-induced DKD mouse model with adeno-associated virus-mediated Smad3 overexpression was established to evaluate renal function, fibrosis, and associated molecular changes. Enoxolone was identified as a key candidate capable of reversing collagen expression disorder in proximal tubular epithelial cells treated with high glucose and AGEs. It binds directly to the Arg292 site in the MH2 domain of Smad3 with a high affinity. Enoxolone significantly inhibited the formation of the Smad3-Smad4 complex, reduced the enrichment of Smad3 on the COL1A1 promoter, and downregulated COL1A1 expression. In DKD mice, enoxolone reduced blood urea nitrogen, serum creatinine, and renal hydroxyproline levels and alleviated collagen deposition and tubular injury, whereas Smad3 overexpression reversed these effects. Enoxolone targets Arg292 of Smad3, inhibiting Smad3-Smad4 complex formation and downstream pro-fibrotic gene transcription, thereby attenuating renal fibrosis in DKD. Enoxolone has emerged as a promising anti-fibrotic candidate for the treatment of DKD.
-
3. Risk Factors for All-Cause and Cause-Specific Mortality in Patients with Chronic Kidney Disease: Age-Specific Associations and Attributable Burden.
3. 慢性肾脏病患者全因及特因死亡的危险因素：年龄特异性关联与归因负担PMID:日期:2026-07-10Evidence regarding age-specific associations between risk factors and mortality in patients with chronic kidney disease (CKD) remains limited. We sought to investigate these age-specific associations and to measure their attributable burden on mortality. This population-based, retrospective cohort study included 576,677 patients in Hong Kong (73.5 ± 13.8 years, 2008-2020). We assessed all-cause and seven cause-specific mortality. Risk factors included six modifiable risk factors (smoking, blood pressure, fasting blood glucose/hemoglobin A1c, low-density lipoprotein cholesterol [LDL-C], and body mass index) and four major comorbidities (diabetes, cardiovascular disease [CVD], heart failure, and cancer). Using hazard ratios and population-attributable fractions (PAFs), we compared the associations and mortality burden of these risk factors across five age-groups (18 to ≥85 years). During a median follow-up of 4.8 years, 329,098 (57.1%) patients died, with primary death causes being CVD (9.9%), cancer (9.9%), and kidney diseases (4.7%). Despite a higher absolute mortality risk in older patients, the relative risk of most risk factors declined with age. Collectively, all risk factors accounted for a higher mortality proportion in the youngest group (PAF: 44.3% [95% confidence interval: 35.3%, 52.0%]) than in the oldest group (22.6% [14.6%, 29.7%]). For patients aged 18-54, suboptimal LDL-C control (12.0% [8.0%, 15.8%]) was the leading risk factor, while CVD (12.6% [12.1%, 13.1%]) was the most influential factor in patients aged ≥75. The evaluated risk factors were associated with increased relative mortality risks in younger CKD patients. These findings underscore the importance of early management strategies, emphasizing LDL-C control in younger and CVD prevention in older CKD patients.
-
4. Relationship of Renal Replacement Therapy to Cancer Site: A Hospital-Based Analysis in Osaka, Japan.
PMID:日期:2026-07-10Cancer patients are at risk for acute kidney injury (AKI) due to anticancer agents, tumor lysis syndrome, sepsis, and contrast-induced nephropathy. Renal replacement therapy (RRT) is associated with longer hospital stays, higher healthcare costs, and significant healthcare resource consumption. Therefore, early detection of severe AKI requiring RRT and the implementation of preventive measures are crucial. We comprehensively evaluated the associations with RRT by cancer site among Japanese cancer patients undergoing treatment through use of Hospital-Based Cancer Registry (HBCR) data linked to administrative data in a multicenter cohort study. Patients were classified into three groups based on the timing of RRT after the initiation of cancer treatment: acute phase (≤30 days), post-acute phase (after 30 days), and no RRT. The hazard ratios (HRs) and subdistribution HRs for RRT incidence were evaluated by cancer site (colon, lung, stomach, liver, kidney, esophagus, pancreas, and hematologic malignancies) using Cox proportional hazards and Fine-Gray competing-risk models adjusted for patient characteristics, comorbidities, and diuretic use. The 1-year cumulative incidence of RRT was also calculated. A total of 230,850 patients were analyzed. Among them, 386 patients received RRT at ≤30 days after cancer treatment initiation (acute phase), 479 patients received RRT at >30 days (post-acute phase), and 229,985 patients did not receive RRT. In the Cox proportional hazards regression model, the HRs for RRT were significantly higher in the acute phase among patients with colorectal cancer (HR: 1.72, < 0.001), liver cancer (HR: 1.80, = 0.006), kidney cancer (HR: 2.49, < 0.001), and hematologic malignancies (HR: 4.06, < 0.001) when compared according to cancer site. In the post-acute phase, only hematologic malignancies showed a significantly increased HR for RRT (HR: 2.65, < 0.001). The 1-year cumulative incidence of RRT among all patients was 0.413%. The risk of RRT after cancer treatment was increased during the acute phase in patients with colorectal, liver, and kidney cancer and those with hematologic malignancies. Patients with hematologic malignancies always had a higher HR for RRT, but the HR was particularly high in the acute phase.
-
5. Safety and Efficacy of the First Mobile Intelligent Hemodialysis Platform in Mainland China: Protocol for a Single-Center Prospective Exploratory Study in Maintenance Hemodialysis Patients.
5. 中国大陆首个移动智能血液透析平台的安全性和有效性：维持性血液透析患者单中心前瞻性探索性研究方案PMID:日期:2026-07-10End-stage kidney disease (ESKD) is a growing global public health burden, with millions of patients dependent on maintenance hemodialysis (MHD). Conventional center-based MHD imposes significant constraints on patient flexibility, accessibility, and quality of life, while home hemodialysis faces substantial implementation barriers in China. Advances in digital health technologies - including artificial intelligence, internet of things (IoT), and real-time data analytics - offer opportunities to fundamentally transform dialysis care delivery. This study presents the protocol for the first clinical trial evaluating a mobile intelligent hemodialysis platform in mainland China. This is a prospective, single-center, exploratory clinical trial to be conducted at Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine. Twenty adult ESKD patients (aged 18-75 years) receiving regular MHD 3 times weekly for at least 3 months will be enrolled. Participants will undergo a single 4-h hemodialysis session on the mobile intelligent dialysis platform, a specialized medical vehicle integrating water purification, dialysis equipment, and an intelligent clinical decision support system across six functional zones. The primary endpoint is the successful session completion rate, defined as completion without platform-related technical failure or premature termination. Secondary endpoints include dialysis adequacy (urea reduction ratio ≥65%; Kt/V >1.2), hemodynamic stability, and pre- to post-dialysis changes in biochemical parameters. Safety assessments include continuous vital sign monitoring and adverse event grading according to Common Terminology Criteria for Adverse Events (CTC-AE) version 4.0. The study has been approved by the Ethics Committee of Ren Ji Hospital (approval number: LY2024-313-A) and registered in the Chinese Clinical Trial Registry (ChiCTR2500100356). This trial is expected to demonstrate that the mobile intelligent hemodialysis platform can achieve high session completion rates, adequate dialysis efficiency, and a safety profile comparable to conventional center-based dialysis. If validated, this platform has the potential to improve service accessibility, reduce indirect costs, enhance patient autonomy, and provide a resilient dialysis option in public health emergencies and disaster settings, representing a meaningful paradigm shift in dialysis care delivery.
-
6. Efficacy and Cardiovascular Safety of Pegmolesatide in Patients with Anemia of Chronic Kidney Disease: Post hoc Analysis of Two Phase 3 Randomized Trials.
PMID:日期:2026-06-18Pegmolesatide selectively binds to the erythropoietin receptor homodimer with higher binding stability and prolonged residency than erythropoietin, potentially offering an improved therapeutic profile for anemia management in chronic kidney disease (CKD) patients. This post hoc analysis of two randomized phase 3 trials compared pegmolesatide with epoetin alfa to further evaluate pegmolesatide's potential benefits. This analysis included a total of 545 patients: 372 with dialysis-dependent (DD)-CKD (248 pegmolesatide, 124 epoetin alfa) and 173 with non-dialysis-dependent (NDD)-CKD (115 pegmolesatide, 58 epoetin alfa). The proportion of patients maintaining mean hemoglobin (Hb) levels ≥10 g/dL and intraindividual hemoglobin variability (Hb-Var) were analyzed. Cardiovascular (CV) safety was assessed using five-point major adverse cardiovascular events (MACE), expanded CV events, and three-point MACE. During the efficacy evaluation period (weeks 17-24), pegmolesatide showed numerically higher proportions of patients who maintained mean Hb levels ≥10 g/dL versus epoetin alfa in both DD-CKD {91.8% vs. 88.6%; difference: 7.1% (95% confidence interval [CI]: 0.1, 14.2); = 0.2802} and NDD-CKD (87.0% vs. 85.4%; difference: 3.3% [95% CI: -8.1, 14.6]; = 0.6091) patients. From the efficacy evaluation period to the extended period (weeks 17-52), patients receiving pegmolesatide exhibited lower Hb-Var compared with those receiving epoetin alfa as measured by within-patient residual standard deviation (DD-CKD: 0.678 g/dL vs. 0.730 g/dL, = 0.0061; NDD-CKD: 0.647 g/dL vs. 0.677 g/dL, = 0.3158). The incidences of five-point MACE (DD-CKD: 3.7% vs. 6.5%, hazard ratio [HR] = 0.54 [95% CI: 0.21, 1.39]; NDD-CKD: 0.9% vs. 6.9%, HR = 0.14 [95% CI: 0.02, 1.28]), expanded CV events (DD-CKD: 9.8% vs. 11.3%, HR = 0.83 [95% CI: 0.43, 1.61]; NDD-CKD: 5.2% vs. 12.1%, HR = 0.49 [95% CI: 0.16, 1.45]) and three-point MACE (DD-CKD: 2.0% vs. 3.2%, HR = 0.60 [95% CI: 0.16, 2.23]; NDD-CKD: 0 vs. 1.7%, HR not estimable) were consistently lower in the pegmolesatide group across both patient populations. Pegmolesatide showed effectiveness in Hb management for both NDD-CKD and DD-CKD populations, with overall numerically favorable CV safety outcomes compared to epoetin alfa.
-
7. Therapeutic Applications of Induced Pluripotent Stem Cell Technology in Kidney Disease: A Systematic Review and Meta-Analysis.
7. 诱导多能干细胞技术在肾脏疾病中的治疗应用：系统综述和荟萃分析PMID:日期:2026-06-18Kidney disease is a major global health burden with limited regenerative treatment options. Induced pluripotent stem cells (iPSCs) offer patient-specific pluripotency and the potential to generate renal cells and organoids, making them a promising approach for kidney repair. A systematic literature search was conducted in PubMed, ScienceDirect, Web of Science, and Cochrane Library for peer-reviewed studies investigating the therapeutic application of iPSCs in kidney disease up to February 2026. Risk of bias was assessed using the SYRCLE tool. Random effects meta-analyses were performed, and subgroup and meta-regression analyses were conducted to explore potential sources of heterogeneity. In this search, 23 preclinical studies encompassing 372 animals met the inclusion criteria, and no eligible human trials were identified. iPSC-based therapy was associated with reduced mortality (OR = 0.17; 95% CI: 0.05-0.52; = 0.002) and improvements in blood urea nitrogen, serum creatinine, and histological injury scores. Subgroup and meta-regression analyses suggested that therapeutic response was influenced by biological factors, including cell type, disease model, delivery route, and treatment conditions. Notably, stronger effects were observed in acute kidney injury models and with direct iPSC-based interventions. However, substantial heterogeneity was observed across most renal outcomes ( > 90%), indicating considerable variability among studies. iPSC-based therapy demonstrates beneficial effects in experimental kidney disease, particularly in acute models. However, the high degree of heterogeneity, potential risk of bias, and limited safety data constrain the reliability and generalizability of these findings. Further optimization of therapeutic strategies and rigorous long-term safety evaluations are required to support clinical translation.
-
8. Clinicopathological Characteristics and Prognostic Implications of Periodic Acid-Schiff-Positive Amyloid Deposits in Renal AL Amyloidosis.
8. 肾AL淀粉样变性中高碘酸Schiff阳性淀粉样蛋白沉积的临床病理特征和预后意义PMID:日期:2026-06-15It has been recognized that periodic acid-Schiff (PAS) staining of amyloid deposits is typically weak or negative in the majority of AL amyloidosis. However, a subset of patients exhibits PAS-positive deposits, and their clinicopathological significance remains unclear. We retrospectively analyzed 269 patients with renal biopsy-proven AL amyloidosis from our institution; 72 were classified as PAS positive and 197 as PAS negative. Baseline demographics, clinical data, renal pathology features, treatment strategies, and prognostic information were collected. Multivariable linear regression and Cox proportional hazards models were used to determine the impact of PAS-positive amyloid deposition on renal function and patients' outcomes. Compared with the PAS-negative group, PAS-positive patients had higher serum creatinine (94.40 vs. 79 μmol/L, = 0.005) and increased renal insufficiency ratio (31.94% vs. 14.72%, = 0.002). Histopathology showed more severe glomerular and interstitial amyloid deposition ( = 0.037, = 0.049, respectively). In multivariable linear regression, PAS-positive deposits (β = 0.158, = 0.005) were independently associated with higher serum creatinine. PAS-positive patients showed significantly worse renal survival (HR: 3.05, 95% CI: 1.40-6.65, = 0.005), independent of age, treatment regimens, renal stage, and pathological cores. Meanwhile, PAS-positive staining was an adverse prognostic factor (HR: 2.34, 95% CI: 1.24-4.43, = 0.009) for overall survival after adjusting for AL type, age, treatment, organ involvement, interstitial fibrosis and tubular atrophy, and total amyloid burden. PAS-positive amyloid deposits are associated with more severe renal injury and poorer prognosis in AL amyloidosis.
-
9. Elevated Serum LL37 and Myeloperoxidase-DNA Complexes Predict the Progression of Diabetic Kidney Disease.
9. 血清LL37和髓过氧化物酶DNA复合物升高可预测糖尿病肾病的进展PMID:日期:2026-06-12Predicting early progression of diabetic kidney disease (DKD) remains challenging. The neutrophil-derived peptide LL37 is implicated in kidney inflammation, yet its role and prognostic value in DKD remain unclear. RNA sequencing dataset was analyzed to examine the expression of CAMP (encoding LL37) and myeloperoxidase (MPO) in peripheral blood from diabetic mellitus patients. A clinical cohort of 94 biopsy-proven DKD patients and 63 healthy controls (HCs) was established. Serum LL37 and MPO-DNA complexes were measured using enzyme-linked immunosorbent assay. The correlation between serum LL37 and MPO-DNA complex levels and kidney function was assessed and assessed their association with DKD progression using restricted cubic spline analysis and Cox proportional hazards regression models. Bioinformatics analysis revealed significantly elevated CAMP expression in DM patients, with strong neutrophil infiltration. In the clinical cohort, serum LL37 levels were significantly higher in DKD patients than in HC, showing discriminatory power for DKD diagnosis (AUC = 0.90, 95% CI: 0.85-0.96). Serum LL37 and MPO-DNA complex levels correlate with elevated serum creatinine and reduced eGFR. After a median follow-up of 39 months, 60 patients (63.83%) experienced renal progression events. After adjusting for confounding factors, elevated serum LL37 and MPO-DNA complex levels were independent risk factors for DKD progression (per Ln-transformed HRs: 2.290 [95% CI: 1.491-3.518] and 1.833 [95% CI: 1.261-2.664], respectively). Elevated serum LL37 and MPO-DNA complex levels are independently associated with kidney disease progression in patients with DKD, and increased circulating LL37 may be closely linked to neutrophil activation.
-
10. Differential Associations of Iron Deficiency with Renal Progression and Mortality in Anemic Non-Dialysis-Dependent Chronic Kidney Disease.
PMID:日期:2026-06-12Iron deficiency is prevalent in chronic kidney disease (CKD), particularly among patients with anemia. However, the prognostic value of routinely measured iron biomarkers, ferritin and transferrin saturation (TSAT), in non-dialysis-dependent (NDD) CKD remains incompletely defined. We conducted a multicenter retrospective cohort study using data from the China Renal Data System. Eligible hospitalized adults had anemia and NDD-CKD with baseline serum ferritin or TSAT measurements. Iron deficiency was defined as ferritin ≤100 ng/mL and/or TSAT ≤20%. The primary outcomes were CKD progression and all-cause mortality. Associations were assessed using multivariable Cox proportional hazards models; Fine and Gray competing risk models and prespecified subgroup analyses evaluated robustness. Among 40,667 patients with anemic CKD, 38,307 had ferritin measurements, and 9,210 had TSAT measurements. Of these, 11,116 (29.02%) had ferritin ≤100 ng/mL and 3,295 (35.78%) had TSAT ≤20%. During follow-up, CKD progression occurred in 8,756 (22.86%) patients in the ferritin cohort and 2,459 (26.70%) in the TSAT cohort. In multivariable analyses, ferritin ≤100 ng/mL was associated with a modestly lower risk of CKD progression than levels greater than 100 ng/mL (adjusted hazard ratio [aHR], 0.95; 95% confidence interval [CI], 0.90-0.99), with similar results in competing risk analyses. TSAT ≤20% was not associated with CKD progression (aHR, 1.04; 95% CI, 0.95-1.13). For all-cause mortality, ferritin ≤100 ng/mL was not independently associated with risk (aHR, 0.99; 95% CI, 0.93-1.06), whereas TSAT ≤20% was associated with higher risk (aHR, 1.19; 95% CI, 1.06-1.36). CRP-stratified analyses indicated that ferritin ≤100 ng/mL was associated with lower CKD progression risk only among patients with CRP ≤10 mg/L, suggesting that the prognostic association of ferritin varied by inflammatory status. In Chinese adults with anemia and NDD-CKD, ferritin and TSAT showed divergent prognostic associations. TSAT ≤20% identified higher mortality risk, whereas ferritin ≤100 ng/mL was associated with a modestly lower observed risk of CKD progression in an inflammation-dependent pattern. These findings support routine, context-aware assessment of iron indices, particularly TSAT, in anemic NDD-CKD.